New study shows how to optimize the blood sugar of diabetes patients
Posted November 01, 2019 10:17:30A new study of people with type 2 diabetes has shown that, when combined with medication, insulin treatment can lower the risk of developing diabetes, a finding that could pave the way for better treatments for the disease.
The researchers studied people with diabetes from the National Health and Nutrition Examination Survey (NHANES) in the U.S. The researchers also analyzed data from the Nurses Health Study, which tracks about 2 million people over 10 years.
The study, published in the Journal of the American Medical Association, showed that patients who took an average of 12.5 doses of insulin daily in the last three months had a 20 percent lower risk of diabetes-related death compared with those who took a lower dose of insulin.
“It shows that insulin has a very important role in controlling blood sugar,” said lead researcher Eric K. Hagen, a professor of medicine at Harvard Medical School in Boston.
The risk of death associated with type 1 diabetes is roughly two times greater than that associated with diabetes that is not treated.
But the risk is not always as great, as people who take more than six doses of medication have a 50 percent higher risk of dying than those who take fewer than three doses, the researchers wrote.
The data also showed that insulin, as well as some drugs, can help control diabetes.
“The insulin combination is one of the most powerful and effective treatments for type 2 diabetics,” Dr. Hagan said.
Dr. Hagon said that in addition to improving insulin levels, he believes the combination of insulin and medication should be considered as a possible treatment option for type 1 diabetians.
He said the combination may also help control the risk for diabetes-associated complications, such as heart disease.
A previous study, by another team of researchers at Harvard, found that combining insulin and a drug that blocks the release of a protein in the pancreas can help people with Type 1 diabetes.
The study was published in Diabetes Care.
The NHANES data showed that the combined insulin dose decreased the risk in people who took at least three doses of drugs or who took medication twice or more in a row, the study authors wrote.
The insulin combination had no effect in people taking fewer than six pills or one drug.
The new study included 2,076 people who were diagnosed with type II diabetes in the NHANes data.
About 1,200 of the participants were taking insulin.
People with type 3 diabetes, which includes people with non-insulin-dependent diabetes, have insulin levels that can be up to 5.5 times higher than people with insulin-dependent type 1.
People with type 4 diabetes have levels that are lower than people without diabetes.
Hagen said the study was a step in the right direction.
“This is a very interesting finding, but the next step is to make sure that we can use it in a clinical setting and get these patients on insulin,” he said.
Hag said it could be possible to make a treatment that lowers the risk more effective than the drugs alone.
The Harvard study, which was funded by the National Institutes of Health, looked at the risk associated with insulin doses of 12 to 16.5 mg/day, while the Nursers Health Study looked at 12.75 to 18.75 mg/d.
The drugs in the Nurser Health Study were given to people at a higher risk for developing diabetes.
The drug in the Harvard study was an anti-inflammatory drug called arginine monophosphate.
It is also the main ingredient in the pill Glucagon, which is used to treat Type 1.
The Drug Enforcement Administration has said Glucagons, which are used to control blood sugar in Type 1 and Type 2 diabetes, are not approved for people over the age of 35.
The FDA has not approved Glucogins for people under 35.
The Nursers study, funded by Pfizer, looked for a drug called interferon beta-1a, or ibuprofen, that was administered in combination with insulin or a drug known as metformin.
The Interferon Beta-1b study looked for the drug ticagrelor, which blocks the ability of the immune system to fight infections, the investigators said.
The drug is also used in combination therapy for cancer and heart disease, they said.
Both studies are available at the American Diabetes Association website.
The National Institutes on Aging is a private nonprofit organization.
The National Institutes are funded by private donors and the taxpayers of the United States.
For more news videos visit Yahoo View, available now on iOS and Android.